Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DB26FNMMW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $82,042
Award facts
- Contract value 100% obligated
- $82,041.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $82,041.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The award was issued on October 17, 2025, with an ultimate completion date of November 7, 2025, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion strategic acquisition vehicle designed to provide comprehensive pharmaceutical and medical consumable support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, with a diversified product portfolio spanning oncology treatments, biologics, vaccines, specialty pharmaceuticals, and routine medications. The PPV-G GEN V contract, awarded on November 13, 2025, with a ceiling value of $499.999 billion and completion date of December 31, 2036, establishes the company as a critical regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. This structure enables the Defense Logistics Agency to efficiently source specialized pharmaceutical products, such as the Keytruda supply represented in this delivery order, to support global military healthcare operations without requiring competitive re-solicitation for each individual requirement.
Quick answers
Who was awarded contract SPE2DB26FNMMW?
SPE2DB26FNMMW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 17, 2025.
How much is contract SPE2DB26FNMMW worth?
The government has obligated $82,042 on SPE2DB26FNMMW.
Is contract SPE2DB26FNMMW an order under another contract?
Yes. SPE2DB26FNMMW is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMMW competed?
The extent of competition for SPE2DB26FNMMW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award